Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2023 May; Vol. 53 (5), pp. 339-356. Date of Electronic Publication: 2023 Aug 29.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.

Authors : Kollipara S; KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India.; Ahmed T

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics ; Diltiazem*; Cytochrome P-450 CYP2C19

Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2023 May; Vol. 53 (5), pp. 366-381. Date of Electronic Publication: 2023 Sep 04.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.

Authors : Mulford DJ; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.; Ramsden D

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics ; Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/pharmacokinetics; Humans

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Apr; Vol. 12 (4), pp. 532-544. Date of Electronic Publication: 2023 Mar 10.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open-Label, Sequential Crossover, Self-Control, 3-Period Study in Healthy Chinese Volunteers.

Authors : Yuan F; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.; Li J

Subjects: Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/adverse effects ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacology; Humans

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Feb; Vol. 12 (2), pp. 168-174. Date of Electronic Publication: 2022 Dec 30.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.

Authors : Tariq B; Clinical Pharmacology, BeiGene USA, Inc, Fulton, MD, USA.; Ou YC

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/adverse effects ; Neoplasms*; Humans

Source: Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 329-338. Date of Electronic Publication: 2022 Dec 08.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Physiologically-based pharmacokinetic modeling for primary metabolites of CYP3A and P-glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?

Authors : Yamazaki S; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, LLC, San Diego, California, USA.; Evers R

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jan; Vol. 12 (1), pp. 8-12. Date of Electronic Publication: 2022 Nov 11.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).

Authors : Vandenbossche J; Janssen Pharmaceutica NV, Beerse, Belgium.; Yogaratnam J

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacology ; Hepatitis B virus*/Hepatitis B virus*/Hepatitis B virus*/metabolism; Adult

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Dec; Vol. 11 (12), pp. 1419-1429. Date of Electronic Publication: 2022 Sep 05.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.

Authors : Li X; Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, USA.; Shelton MJ

Subjects: Cytochrome P-450 CYP3A Inducers* ; Cytochrome P-450 CYP3A Inhibitors* ; Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/Protein Kinase Inhibitors*/pharmacokinetics

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Oct; Vol. 11 (10), pp. 1165-1176. Date of Electronic Publication: 2022 May 13.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Identification of Potential Cytochrome P450 3A5 Inhibitors: An Extensive Virtual Screening through Molecular Docking, Negative Image-Based Screening, Machine Learning and Molecular Dynamics Simulation Studies.

Authors : Islam MA; 3BIGS Omicscore Private Limited, 909 Lavelle Building, Richmond Circle, Bangalore 560025, India.; Dudekula DB

Subjects: Cardiovascular Diseases* ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/chemistry ; Molecular Dynamics Simulation*

Source: International journal of molecular sciences [Int J Mol Sci] 2022 Aug 19; Vol. 23 (16). Date of Electronic Publication: 2022 Aug 19.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A Phase 1, Open-Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects.

Authors : Trivedi A; Amgen Inc, Thousand Oaks, California, USA.; Mather O

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/adverse effects ; Itraconazole*/Itraconazole*/Itraconazole*/adverse effects ; Itraconazole*/Itraconazole*/Itraconazole*/pharmacokinetics

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Jul; Vol. 11 (7), pp. 849-856. Date of Electronic Publication: 2022 Mar 05.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي